Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Linda A. Chatman"'
Autor:
Rama Y. Chandrasekaran, Jiri Aubrecht, Frederick R. Nelson, Linda A. Chatman, Hans Rollema, Frank M. Nedza, John M. Marcek, Philip A. Iredale, Jennifer B. Munzner, Betty Pettersen, Raggon Jeffrey W, David M. Rubitski, Julie Cianfrogna, Larry C. James, Karen W. Cook, Michael J. Banker, Diane F. Wong, Anne W. Schmidt, Michael Homiski, Howard Harry R, Daniel J. Lettiere, Butler Todd W, Scot Richard Mente, Jody Freeman, Travis T. Wager, Douglas K. Spracklin
Publikováno v:
Journal of Medicinal Chemistry. 54:7602-7620
The discovery of two histamine H3 antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in iden
Autor:
E. Kadyszewski, Robert E. Chapin, K.K. Terry, Linda A. Chatman, Mark E. Hurtt, T.L. Fleeman, G.L. Foley
Publikováno v:
Birth Defects Research Part B: Developmental and Reproductive Toxicology. 74:431-441
BACKGROUND: Feed restriction with its resultant body weight loss impacts the rodent estrous cycle; however, the manifestation of these changes in a regulatory study design has not been documented. This study reports the effects of feed restriction in
Autor:
Norimitsu Shirai, Linda A. Chatman, Natasha Neef, John C. Pettersen, Karen Walters, John Litchfield, Jeffrey A. Pfefferkorn, Bradley E. Enerson, Stephen P. Schmidt
Publikováno v:
Toxicologic pathology. 42(4)
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs, and/or monkeys. GKAs were administered for 2 to
Autor:
Travis T, Wager, Betty A, Pettersen, Anne W, Schmidt, Douglas K, Spracklin, Scot, Mente, Todd W, Butler, Harry, Howard, Daniel J, Lettiere, David M, Rubitski, Diane F, Wong, Frank M, Nedza, Frederick R, Nelson, Hans, Rollema, Jeffrey W, Raggon, Jiri, Aubrecht, Jody K, Freeman, John M, Marcek, Julie, Cianfrogna, Karen W, Cook, Larry C, James, Linda A, Chatman, Philip A, Iredale, Michael J, Banker, Michael L, Homiski, Jennifer B, Munzner, Rama Y, Chandrasekaran
Publikováno v:
Journal of medicinal chemistry. 54(21)
The discovery of two histamine H(3) antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in id
Publikováno v:
Birth defects research. Part B, Developmental and reproductive toxicology. 92(4)
BACKGROUND: CP-601927 is a selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist. The objective of this study was to assess the potential effects persisting into adulthood when CP-601,927 was administered to neonatal/juvenile rats
Publikováno v:
Toxicologic pathology. 37(7)
Drug-induced phospholipidosis (PL) is an excessive accumulation of phospholipids and drug in lysosomes. Phospholipidosis signals a change in cell membrane integrity and accumulation of intracellular drug or metabolite in tissues. The sensitivity and
Autor:
Brian R, Berridge, Linda A, Chatman, Marielle, Odin, Albert Eric, Schultze, Patricia E, Losco, James T, Meehan, Terry, Peters, Steven L, Vonderfecht
Publikováno v:
Toxicologic pathology. 35(2)
Autor:
Linda A. Chatman, Brian R. Berridge, Patricia E. Losco, James T Meehan, Albert E. Schultze, Marielle Odin, Steven Vonderfecht, Terry Peters
Publikováno v:
Toxicologic Pathology. 35:325-325